Development Services

Standard Offerings 
• Granulation & Mixing  • Fluid Bed Processing & Drying • Hot Melt Extrusion  • Pan Coating  • Blending  • Tableting  • Bilayer Tablets  • Capsule Filling  • Oven Drying  • Spray Drying • Small-scale ...

Adare’s industry-leading experts possess unparalleled experience in the development of unique dosage forms that provide taste masking, customized release, and patient-centric solutions. Our technology platforms overcome complex formulation challenges to improve the lives of all patients, with expertise in ...

Clinical & Commercial Packaging Services
• High-speed bottle filling • Blister packaging • Stick pack filling • Flow wrap packaging • Clinical supply services • Repackaging license • Packaging of DEA Schedules II, 2N, III, 3N, IV, L1  • Serialization & aggregation

Very few CDMOs can claim Adare's level of experience in mitigating the presence of nitrosamine. We can employ our own-in-house mitigation processes to develop the best long-term control strategies for your product. 

Regain control of your product with NitroCLEARx • Receive real-world mitiga...

AdvaTab Advanced ODT technology offers an easy-to-ingest solution ideal for pediatric, geriatric, and dysphagic patients. The tablets are composed of finely micronized particles that rapidly disintegrate into a smooth, viscous suspension. This innovative dosage form effectively masks the bitter taste of me...

Microcaps® Taste Masking and Modified Release Technology achieves uniform and efficient coating of drug particles by coacervation (phase separation) to build polymeric membranes of varying porosity and thickness. The result is a free-flowing powder containing microencapsulated API (or API substrate) in a w...

Diffucaps® is a controlled-release technology that offers multiple benefits for drug products by effectively controlling drug delivery and optimizing release profiles. It allows for adjustable dosage strength and dissolution characteristics to achieve the desired in vivo pharmacokinetic profile. Diffu...

The Optimµm® technology creates microspheres with high drug loading suitable for taste masking, enteric coatings, and extended release oral applications. The technology is capable of producing single- or double-layer particles in a one manufacturing step, lending to cost-effective creation of palatabl...

The MMTS™ (Multi Mini Tablet System) offers the flexibility of multiparticulate dosage forms, enabling versatile dose delivery through various formats such as capsules, sachets, and sprinkles. This system allows for a wide range of customized release profiles within a single capsule, supporting precise del...

Adaptdose™, Adare’s unique commercialized approach to adaptive formulation design, is a highly flexible, multi-delivery platform tool that eliminates the need for post Phase 1 trial reformulations and facilitates the creation of custom oral delivery systems. Adaptdose provides the ability to combine 2-3 ac...

Duragran™ allows for more uniformity and precise control of targeted particle sizes while providing production time and cost savings. It eliminates the need for extrusion and spheronization for high API-loaded drug particulates by using fluid bed processing technology that combines the particle sizing and ...

Parvulet® is an oral solid dosage form ideal for pediatric, geriatric, and dysphagic patients, including those with mucositis or swallowing difficulties. With a small amount of water, it forms a texture similar to applesauce, allowing for easy administration in just 30 seconds. Its built-in swallowing...

We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.

Explore Adare's capabilities through our interactive brochure, showcasing our technology-driven CDMO with integrated end-to-end services. With extensive capacity, experience, and a global track record, Adare is your partner for small molecule oral solid dose success.

In Philadelphia in May on site at CPHI North America we were able to meet with some of our speakers regarding their presentations. In the following interview Srinivasan Shanmugam, Executive Director, Pharmaceutical Sciences, Business Support, and New Technologies at Adare Pharma Solutions discusses his breakfast session. 

In a constantly evolving pharmaceutical industry, Adare’s manufacturing offerings give you the edge to overcome uncertainty and reach the market faster.Our integrated CDMO services can support your product’s journey from concept to commercialization, and our extensive manufacturing capabilities make Adare the ideal partner for today’s complex landscape.

Throughout CPHI North America 2023, several Breakfast Sessions were held to start the day off right with a complimentary breakfast and a networking and learning session for our attendees. With insightful presentations from industry experts and partners, the CPHI North America Breakfast Sessions had something for everyone looking to fill their brains and their stomachs. 

A midsize pharmaceutical company partnered with Adare Pharma Solutions to support a secure dosing solution that helps prevent misuse and improve patient compliance by dispensing a precise dosage at scheduled times.

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

When a large CDMO couldn’t give a mid-size pharma company the proper attention, Adare stepped in to help manufacture CTM batches and get their project to the clinic quickly.

3D screen printing provides innovative drug development capabilities that are difficult or impossible to achieve with traditional methods, including complex multi-layered formulations, precision control over drug release profiles, and near-endless possibilities in the geometric shaping of dosage forms. Learn how 3D screen printing offers the unmatched flexibility to tailor formulations for specific therapeutic needs, redefining what’s possible in drug development and manufacturing.

3D screen printing is transforming how medicines are developed and delivered. From personalized dosing to advanced formulations, this technology is opening new opportunities in pharmaceutical development. Adare’s Steven Facer and Laxxon Medical’s Klaus Kuhne discuss how 3D screen printing is shaping the future of drug development.

To make administration of an effective drug treatment easier for patients with hand tremors or swallowing difficulties, Adare Pharma Solutions developed a convenient sprinkle formulation.

Medication acceptance and adherence are critical concerns in pediatric populations due to these patients’ rapid anatomical and physiological development. Additionally, vastly different pharmacokinetics and pharmacodynamics apply when moving through growth stages from neonates to adolescents. This diversity — combined with a limited market size, a complex formulation process, and stringent regulation — makes the design and development of patient-centric pediatric formulations challenging.

It can be easy to overlook the importance of early-stage pharmaceutical product development, viewing it as a series of checklist tasks slowing progression toward clinical trials. Rather, early-stage development is critical to establish a solid foundation for those trials. Success at this point in development means constructing a clear quality target product profile (QTPP) to drive positive proof of concept (PoC) results, all while considering scalability at each step to minimize development challenges downstream.

Dr. Luigi Boltri and Dr. Nasrin Mahmoudi discuss several taste masking strategies that drug developers can implement to improve a drug’s palatability and increase its potential for greater patient adherence.

A combination of two innovative dosing technologies – AbbatiaLabs SA’s POWDOSE® and Adare Pharma Solutions’ Diffucaps® – were the subject of a recent study exploring their use as a powerful solution for precise, individualized dosing of solid oral medications. Learn more about how these technologies can potentially minimize adverse effects and help achieve optimal therapeutic outcomes.

Treating depression in the elderly is an important mission for health care providers. The maker of a drug used to treat depression asked Adare Pharma Solutions to create a version of their drug that would better serve the geriatric population.

When a client approached Adare Pharma Solutions with the challenge of creating a taste masked and easily swallowed version of their malaria drug, our experts turned to a custom microencapsulation process for the solution.

Developing effective therapies for pediatric populations involves unique and complex challenges. Key considerations include medication acceptance, patient-centered adherence strategies, and the pharmacokinetic and pharmacodynamic (PK/PD) challenges arising from the rapid anatomical and physiological development of pediatric patients. Additionally, pediatric medicine faces constraints such as a limited market size, complex formulation requirements, and specific regulatory demands.

In this interview, Srinivasan Shanmugam, PhD, Adare’s Executive Director of Pharmaceutical Sciences, provides expert insights on these important topics.

Pharmaceutical development is as much an art as it is a science, with experts working to find the best solutions and then formulating them in a manner that is universally accessible, efficacious, and sustainable. This article delves into how customized release for dispersed dosage formats enhances patient acceptance and therapeutic performance.

In the wake of the FDA's latest guidance on nitrosamine contamination, ensuring compliance and safeguarding pharmaceutical products is more critical than ever. This ebook provides a comprehensive roadmap for understanding nitrosamine risks and offers actionable strategies to mitigate potential impurities. Through expert insights from Adare Pharma Solutions, you’ll learn how to remain compliant, identify risks, and implement cutting-edge strategies for nitrosamine mitigation.

The following session has been SOLD OUT. For any inquiries, please contact a member of staff on the day Kickstart your CPHI North America with a coffee and pastry, connect with your peers, and listen to exclusive content surrounding patient-centric development The challenge of ensuring medication acceptance and adherence is particularly acute in special populations, such as pediatric and geriatric groups. These populations exhibit distinct pharmacokinetic and pharmacodynamic profiles due to their unique age-related physiological and biopharmaceutical characteristics. Consequently, the standard approaches to medication formulation often fall short of addressing their specific needs. This presentation will explore the unique aspects of pediatric and geriatric populations, highlighting the limitations encountered in the design and development of dosage forms tailored for them, and how those challenges are overcome. A significant focus will be placed on the strategies that can be employed to overcome these challenges, with an emphasis on Adare’s platform technologies. Through this discussion, we aim to shed light on the critical factors that must be considered in the development of effective, patient-friendly pharmaceutical formulations for pediatric and geriatric patients.

In pharma, it is essential to identify the right partner to ensure a successful outcome. Time and time again, mistakes have been made in this process, causing clinical studies to fail and for the company to take a heavy hit. Want to avoid this? join our one-hour masterclass where we will devise a checklist for choosing your first CDMO. Discussion Points Thinking ahead before executing – why it is essential to map out what you need to achieve in all departments Why creating a business partnership case to potential CDMOs will determine if they are the right fit for you A checklist of the common pitfalls and how to avoid

This session addresses: Pediatric population and their needs, the significance of taste masking, taste masking strategies, and Adare's taste-masking solutions. This session was broadcast as part of the CPHI North America show.